Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro

Antiviral Therapy

Volumn 14, Issue 6, 2009, Pages 797-808

  Thompson, Alex J ^a,b,c   Colledge, Danni ^a   Rodgers, Sally ^a   Wilson, Rachel ^a   Revill, Peter ^a   Desmond, Paul ^c   Mansell, Ashley ^d   Visvanathan, Kumar ^d   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; DIPALMITOYL S GLYCERYLCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; LAMIVUDINE; SINGLE STRANDED DNA; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA REPLICATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIGANDS; LIVER NEOPLASMS; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; VIRUS REPLICATION;

EID: 70350134352     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1294     Document Type: Article

References (31)

1. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:422-431. (Pubitemid 43069226)
2. World Health Organization. Hepatitis B: fact sheet. (Accessed 30 March 2009.) Available from http://www.who. int/mediacentre/factsheets/fs204/en/index. html
3. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
4. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346:1682-1683.
5. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
6. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1-14.
7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-376.
8. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45:102-110. (Pubitemid 46150869)
9. Delaney WE IV, Isom HC. In vitro model systems for studying hepatitis B virus replication. In Lai CL, Locarnini S (Editors). Hepatitis B virus. 1st ed. London: International Medical Press 2002; pp. 55-80.
10. Delaney WE, Isom HC. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998; 28:1134-1146. (Pubitemid 28450278)
11. Preiss S, Thompson A, Chen X, et al. Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 2008; 15:888-900.
12. Liu S, Gallo DJ, Green AM, et al. Role of toll-like receptors in changes in gene expression and NF-kappa B activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect Immun 2002; 70:3433-3442. (Pubitemid 34665980)
13. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005; 28:886-892. (Pubitemid 40740661)
14. Li K, Chen Z, Kato N, Gale M, Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005; 280:16739-16747. (Pubitemid 41389131)
15. Chen RY, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37:27-35. (Pubitemid 36042141)
16. Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D- 2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-betal- arabinofuranosyluracil. Antimicrob Agents Chaemother 2001; 45:2495-2501.
17. Delaney WE. Edwards R, Colledge D, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45:1705-1713. (Pubitemid 32466338)
18. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 1st ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press 1989.
19. Warner N, Locarnini S, Kuiper M, et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007; 51:2285-2292. (Pubitemid 47047302)
20. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47:428-434. (Pubitemid 351280710)
21. Melegari M, Wolf SK, Schneider RJ. Hepatitis B virus DNA replication is coordinated by core protein serine phosphorylation and HBx expression. J Virol 2005; 79:9810-9820. (Pubitemid 41022323)
22. Banerjee P, Biswas A, Biswas T. Porin-incorporated liposome induces Toll-like receptors 2- and 6-dependent maturation and type 1 response of dendritic cell. Int Immunol 2008; 20:1551-1563.
23. Togashi H, Ohno S, Matsuo T, et al. Interferon-gamma, tumor necrosis factor-alpha, and interleukin 1-beta suppress the replication of hepatitis B virus through oxidative stress. Res Commun Mol Pathol Pharmacol 2000; 107:407-417. (Pubitemid 32906185)
24. Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol 2003; 77:4033-4042. (Pubitemid 36350944)
25. Delaney WE, Miller TG, Isom HC. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2′,3′- dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother 1999; 43:2017-2026.
26. Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 2007; 81:7351-7362. (Pubitemid 47047824)
27. Robek MD, Boyd BS, Wieland SF, Chisari FV. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A 2004; 101:1743-1747.
28. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 2005; 102:9913-9917. (Pubitemid 40993667)
29. Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 2007; 76:168-177. (Pubitemid 47410321)
30. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signalling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79:7269-7272. (Pubitemid 40677357)
31. Wu J, Lu M, Meng Z, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007; 46:1769-1778.